Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

A Monoclonal Antibody Specific for Japanese Encephalitis Virus with High Neutralizing Capability for Inclusion as a Positive Control in Diagnostic Neutralization Tests.

Calvert AE, Bennett SL, Dixon KL, Blair CD, Roehrig JT.

Am J Trop Med Hyg. 2019 Jul;101(1):233-236. doi: 10.4269/ajtmh.19-0073.

PMID:
31115302
2.

A DENV-2-type-specific monoclonal antibody binds to the DENV-complex-reactive antigenic site on envelope protein domain 3.

Sarathy VV, Pitcher TJ, Gromowski GD, Roehrig JT, Barrett ADT.

J Gen Virol. 2017 Jun;98(6):1299-1304. doi: 10.1099/jgv.0.000785. Epub 2017 Jun 20.

PMID:
28631593
3.

A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.

Calvert AE, Dixon KL, Piper J, Bennett SL, Thibodeaux BA, Barrett AD, Roehrig JT, Blair CD.

Antiviral Res. 2016 Jul;131:92-9. doi: 10.1016/j.antiviral.2016.04.013. Epub 2016 Apr 26.

4.

Next generation dengue vaccines: A review of the preclinical development pipeline.

Vannice KS, Roehrig JT, Hombach J.

Vaccine. 2015 Dec 10;33(50):7091-9. doi: 10.1016/j.vaccine.2015.09.053. Epub 2015 Sep 28. Review.

5.

Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies.

Porta J, Jose J, Roehrig JT, Blair CD, Kuhn RJ, Rossmann MG.

J Virol. 2014 Sep 1;88(17):9616-23. doi: 10.1128/JVI.01286-14. Epub 2014 Jun 11.

6.

Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcγRIIA-mediated antibody-dependent enhancement of infection.

Chotiwan N, Roehrig JT, Schlesinger JJ, Blair CD, Huang CY.

Virology. 2014 May;456-457:238-46. doi: 10.1016/j.virol.2014.03.031. Epub 2014 Apr 18.

7.

Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.

Julander JG, Thibodeaux BA, Morrey JD, Roehrig JT, Blair CD.

Antiviral Res. 2014 Mar;103:32-8. doi: 10.1016/j.antiviral.2013.12.011. Epub 2014 Jan 3.

8.

West nile virus in the United States - a historical perspective.

Roehrig JT.

Viruses. 2013 Dec 10;5(12):3088-108. doi: 10.3390/v5123088. Review.

9.

Development of a small animal peripheral challenge model of Japanese encephalitis virus using interferon deficient AG129 mice and the SA14-14-2 vaccine virus strain.

Calvert AE, Dixon KL, Delorey MJ, Blair CD, Roehrig JT.

Vaccine. 2014 Jan 3;32(2):258-64. doi: 10.1016/j.vaccine.2013.11.016. Epub 2013 Nov 17.

10.

Mutation of the dengue virus type 2 envelope protein heparan sulfate binding sites or the domain III lateral ridge blocks replication in Vero cells prior to membrane fusion.

Roehrig JT, Butrapet S, Liss NM, Bennett SL, Luy BE, Childers T, Boroughs KL, Stovall JL, Calvert AE, Blair CD, Huang CY.

Virology. 2013 Jul 5;441(2):114-25. doi: 10.1016/j.virol.2013.03.011. Epub 2013 Apr 6.

11.

Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation.

Live Dengue Vaccines Technical Consultation Reporting Group, Bentsi-Enchill AD, Schmitz J, Edelman R, Durbin A, Roehrig JT, Smith PG, Hombach J, Farrar J.

Vaccine. 2013 May 28;31(23):2603-9. doi: 10.1016/j.vaccine.2013.03.038. Epub 2013 Apr 6.

12.

Mutations in the West Nile prM protein affect VLP and virion secretion in vitro.

Calvert AE, Huang CY, Blair CD, Roehrig JT.

Virology. 2012 Nov 10;433(1):35-44. doi: 10.1016/j.virol.2012.07.011. Epub 2012 Jul 31.

13.

A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain.

Thibodeaux BA, Garbino NC, Liss NM, Piper J, Blair CD, Roehrig JT.

Vaccine. 2012 May 2;30(21):3180-7. doi: 10.1016/j.vaccine.2012.03.003. Epub 2012 Mar 13.

14.

A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Thibodeaux BA, Garbino NC, Liss NM, Piper J, Schlesinger JJ, Blair CD, Roehrig JT.

Antiviral Res. 2012 Apr;94(1):1-8. doi: 10.1016/j.antiviral.2012.02.001. Epub 2012 Feb 15.

15.

Recommendations for publication of viral genetic data and sample access for novel viruses and strains.

Arrigo NC, Briese T, Calisher CH, Drebot MA, Hjelle B, LeDuc JW, Powers AM, Repik PM, Roehrig JT, Schmaljohn CS, Tesh RB, Weaver SC.

Am J Trop Med Hyg. 2012 Feb;86(2):189-91. doi: 10.4269/ajtmh.2012.11-0523. No abstract available.

16.

Development of a human-murine chimeric immunoglobulin M for use in the serological detection of human alphavirus antibodies.

Thibodeaux BA, Liss NM, Panella AN, Roehrig JT.

Clin Vaccine Immunol. 2011 Dec;18(12):2181-2. doi: 10.1128/CVI.05269-11. Epub 2011 Oct 5.

17.

Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection.

Hunt AR, Bowen RA, Frederickson S, Maruyama T, Roehrig JT, Blair CD.

Virology. 2011 Jun 5;414(2):146-52. doi: 10.1016/j.virol.2011.03.016. Epub 2011 Apr 13.

18.

Amino acid changes within the E protein hinge region that affect dengue virus type 2 infectivity and fusion.

Butrapet S, Childers T, Moss KJ, Erb SM, Luy BE, Calvert AE, Blair CD, Roehrig JT, Huang CY.

Virology. 2011 Apr 25;413(1):118-27. doi: 10.1016/j.virol.2011.01.030. Epub 2011 Feb 24.

19.

Alphaviruses.

Powers AM, Roehrig JT.

Methods Mol Biol. 2011;665:17-38. doi: 10.1007/978-1-60761-817-1_2.

PMID:
21116793
20.

Human monoclonal antibodies to West Nile virus identify epitopes on the prM protein.

Calvert AE, Kalantarov GF, Chang GJ, Trakht I, Blair CD, Roehrig JT.

Virology. 2011 Feb 5;410(1):30-7. doi: 10.1016/j.virol.2010.10.033. Epub 2010 Nov 16.

21.

Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape.

Gromowski GD, Roehrig JT, Diamond MS, Lee JC, Pitcher TJ, Barrett AD.

Virology. 2010 Nov 25;407(2):237-46. doi: 10.1016/j.virol.2010.06.044. Epub 2010 Sep 15.

22.

Development of human-murine chimeric immunoglobulin G for use in the serological detection of human flavivirus and alphavirus antibodies.

Thibodeaux BA, Panella AN, Roehrig JT.

Clin Vaccine Immunol. 2010 Oct;17(10):1617-23. doi: 10.1128/CVI.00097-10. Epub 2010 Aug 25.

23.

Domain-III FG loop of the dengue virus type 2 envelope protein is important for infection of mammalian cells and Aedes aegypti mosquitoes.

Erb SM, Butrapet S, Moss KJ, Luy BE, Childers T, Calvert AE, Silengo SJ, Roehrig JT, Huang CY, Blair CD.

Virology. 2010 Oct 25;406(2):328-35. doi: 10.1016/j.virol.2010.07.024. Epub 2010 Aug 13.

24.

The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity.

Hunt AR, Frederickson S, Maruyama T, Roehrig JT, Blair CD.

PLoS Negl Trop Dis. 2010 Jul 13;4(7):e739. doi: 10.1371/journal.pntd.0000739.

25.

The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion.

Huang CY, Butrapet S, Moss KJ, Childers T, Erb SM, Calvert AE, Silengo SJ, Kinney RM, Blair CD, Roehrig JT.

Virology. 2010 Jan 20;396(2):305-15. doi: 10.1016/j.virol.2009.10.027. Epub 2009 Nov 12.

26.

Nocodazole delays viral entry into the brain following footpad inoculation with West Nile virus in mice.

Hunsperger EA, Roehrig JT.

J Neurovirol. 2009 May;15(3):211-8. doi: 10.1080/13550280902913255.

PMID:
19444694
27.

Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human flavivirus antibodies.

Thibodeaux BA, Roehrig JT.

Clin Vaccine Immunol. 2009 May;16(5):679-85. doi: 10.1128/CVI.00354-08. Epub 2009 Mar 18.

28.

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses.

Roehrig JT, Hombach J, Barrett AD.

Viral Immunol. 2008 Jun;21(2):123-32. doi: 10.1089/vim.2008.0007. Review.

PMID:
18476771
29.

Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.

Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG.

Nat Struct Mol Biol. 2008 Mar;15(3):312-7. doi: 10.1038/nsmb.1382. Epub 2008 Feb 10.

PMID:
18264114
30.

Flavivirus DNA vaccines--good science, uncertain future.

Petersen LR, Roehrig JT.

J Infect Dis. 2007 Dec 15;196(12):1721-3. doi: 10.1086/523655. No abstract available.

PMID:
18190248
31.

Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.

Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS.

J Virol. 2007 Dec;81(23):12816-26. Epub 2007 Sep 19.

32.

Glycosylation of the dengue 2 virus E protein at N67 is critical for virus growth in vitro but not for growth in intrathoracically inoculated Aedes aegypti mosquitoes.

Bryant JE, Calvert AE, Mesesan K, Crabtree MB, Volpe KE, Silengo S, Kinney RM, Huang CY, Miller BR, Roehrig JT.

Virology. 2007 Sep 30;366(2):415-23. Epub 2007 Jun 1.

33.

A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus.

Hunt AR, Frederickson S, Hinkel C, Bowdish KS, Roehrig JT.

J Gen Virol. 2006 Sep;87(Pt 9):2467-76.

PMID:
16894184
34.

Temporal analyses of the neuropathogenesis of a West Nile virus infection in mice.

Hunsperger EA, Roehrig JT.

J Neurovirol. 2006 Apr;12(2):129-39.

PMID:
16798674
35.

Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge.

Calvert AE, Huang CY, Kinney RM, Roehrig JT.

J Gen Virol. 2006 Feb;87(Pt 2):339-46.

PMID:
16432020
36.

O'Nyong-nyong fever in West Africa.

Posey DL, O'rourke T, Roehrig JT, Lanciotti RS, Weinberg M, Maloney S.

Am J Trop Med Hyg. 2005 Jul;73(1):32. No abstract available.

PMID:
16014827
37.

Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand.

Hombach J, Barrett AD, Cardosa MJ, Deubel V, Guzman M, Kurane I, Roehrig JT, Sabchareon A, Kieny MP.

Vaccine. 2005 Apr 15;23(21):2689-95.

PMID:
15841565
38.

Recombination and flavivirus vaccines: a commentary.

Monath TP, Kanesa-Thasan N, Guirakhoo F, Pugachev K, Almond J, Lang J, Quentin-Millet MJ, Barrett AD, Brinton MA, Cetron MS, Barwick RS, Chambers TJ, Halstead SB, Roehrig JT, Kinney RM, Rico-Hesse R, Strauss JH.

Vaccine. 2005 Apr 27;23(23):2956-8. No abstract available.

PMID:
15811640
39.

Characterization of West Nile viral replication and maturation in peripheral neurons in culture.

Hunsperger E, Roehrig JT.

J Neurovirol. 2005 Feb;11(1):11-22.

PMID:
15804955
40.

Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria.

Halstead SB, Heinz FX, Barrett AD, Roehrig JT.

Vaccine. 2005 Jan 4;23(7):849-56.

PMID:
15603884
41.

Construction of yellow fever/St. Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool.

Pugachev KV, Guirakhoo F, Mitchell F, Ocran SW, Parsons M, Johnson BW, Kosoy OL, Lanciotti RS, Roehrig JT, Trent DW, Monath TP.

Am J Trop Med Hyg. 2004 Nov;71(5):639-45.

PMID:
15569798
42.

Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein.

Roehrig JT, Volpe KE, Squires J, Hunt AR, Davis BS, Chang GJ.

J Virol. 2004 Mar;78(5):2648-52.

43.

Antigenic structure of flavivirus proteins.

Roehrig JT.

Adv Virus Res. 2003;59:141-75. Review.

PMID:
14696329
44.

Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases.

Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, Lanciotti RS, Campbell GL.

Emerg Infect Dis. 2003 Mar;9(3):376-9.

45.

Epitope-blocking enzyme-linked immunosorbent assays for the detection of serum antibodies to west nile virus in multiple avian species.

Blitvich BJ, Marlenee NL, Hall RA, Calisher CH, Bowen RA, Roehrig JT, Komar N, Langevin SA, Beaty BJ.

J Clin Microbiol. 2003 Mar;41(3):1041-7.

46.

Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus.

Chang GJ, Hunt AR, Holmes DA, Springfield T, Chiueh TS, Roehrig JT, Gubler DJ.

Virology. 2003 Feb 1;306(1):170-80.

47.

Improved clarity of meaning from the use of both formal species names and common (vernacular) virus names in virological literature.

Drebot MA, Henchal E, Hjelle B, LeDuc JW, Repik PM, Roehrig JT, Schmaljohn CS, Shope RE, Tesh RB, Weaver SC, Calisher CH; American Committee on Arthropod-borne Viruses, Subcommittee on InterRelationships Among Catalogued Arboviruses.

Arch Virol. 2002 Dec;147(12):2465-72. No abstract available.

PMID:
12491112
48.

West Nile virus encephalitis.

Petersen LR, Roehrig JT, Hughes JM.

N Engl J Med. 2002 Oct 17;347(16):1225-6. Epub 2002 Sep 23. No abstract available.

PMID:
12270973
49.

Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East.

Lanciotti RS, Ebel GD, Deubel V, Kerst AJ, Murri S, Meyer R, Bowen M, McKinney N, Morrill WE, Crabtree MB, Kramer LD, Roehrig JT.

Virology. 2002 Jun 20;298(1):96-105.

50.

The emergence of West Nile virus in North America: ecology, epidemiology, and surveillance.

Roehrig JT, Layton M, Smith P, Campbell GL, Nasci R, Lanciotti RS.

Curr Top Microbiol Immunol. 2002;267:223-40. Review.

PMID:
12082991

Supplemental Content

Loading ...
Support Center